been appropriate. Antibiotics were initially grouped together then later divided into the categories of cotrimoxazole and β-lactams. When Carter and colleagues concluded 14 years ago that antibiotics could be harmful, they also included all antibiotics regardless of class. Shortly thereafter, my colleagues and I published evidence that a specific group of agents recognized to be effective in shigellosis did not have a detrimental effect. Our subsequent studies indicated that prolonged use of similar agents was associated with a lesser risk of hemolytic-uremic syndrome.\(^1\)\(^4\)

One obvious reason for the discrepancies between studies could be the categorization of antibiotics. We initially chose our stratification for shigellosis on the basis that there is considerable evidence that certain antimicrobials do not have any beneficial effect and perhaps have a detrimental effect (for example, antibiotics to which the bacterium is resistant).\(^6\) If shigellosis investigators had pooled all β-lactam agents they may never have seen a benefit attributable to ampicillin, because first-generation oral cephalosporins were ineffective.\(^3\) A wide spectrum of antibiotics may be used to treat patients infected with *E. coli* O157:H7, including erythromycin and metronidazole. Would it be logical to pool such antibiotics or even cephalosporins with cotrimoxazole or ampicillin in analyses, and would they ever be considered as trial agents in a prospective study? Is it logical to pool all medications as shown in Table 1 of the paper by Wong and colleagues?\(^2\) Furthermore, although patient recruitment was delayed, the study by Proulx and colleagues did not show a detrimental effect for cotrimoxazole.\(^10\)

Some in vitro studies have found increased toxin liberation from verotoxigenic *E. coli* isolates exposed to antibiotics.\(^11\)\(^12\) While the latter studies continue to be used as arguments against antibiotic use, recent evidence has indicated that the results are considerably dependent on the methodology.\(^13\)

Therefore, there is still a need for a prospective, randomized controlled study of ampicillin and placebo as suggested over a decade ago.\(^7\) This study should include sufficient numbers of patients, and patients should be recruited early in the course of the illness. The argument for choosing ampicillin over cotrimoxazole in such a trial rests with the unknown but theoretical risk of administering a moderately soluble sulfonamide during an evolving nephropathy. Ampicillin resistance among verotoxigenic *E. coli* remains reasonably low in most regions. Without such studies, the role of some antibiotics in protecting against or complicating verotoxigenic *E. coli* infections will continue to be uncertain.

**Nevivo Cimolai**
Program of Microbiology, Virology and Infection Control
Children and Women’s Health Centre of British Columbia
Vancouver, BC

**References**


---

I read with interest Donald Farquhar’s summary of a recently published article on the risk of hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* infections.\(^7\) I was a bit perplexed by Farquhar’s last sentence: “The findings of this study strongly suggest that these drugs should be withheld in children with acute diarrheal illness until stool cultures confirm growth of an organism for which antibiotic therapy is indicated (e.g., *Campylobacter pylori*).” Did Farquhar mean *Campylobacter jejuni*? *Campylobacter pylori* has been renamed *Helicobacter pylori*. It does not cause a diarrheal illness, nor is it routinely grown from stool cultures.

**Marc Romney**
Department of Medical Microbiology
St. Paul’s Hospital
Vancouver, BC

**References**


A view from the front line

As one of many Canadian physicians working at the front line with little immediate hope of replacement, I note with bemusement that Morris Barer, the coauthor of the Barer-Stoddart report, which recommended that medical school enrolment be slashed, has been
appointed the scientific director of the new Institute of Health Services and Policy Research of the Canadian Institutes of Health Research.1 Please, no more cuts.

Ian Hammond
Department of Radiology
Ottawa Hospital – General Campus
Ottawa, Ont.

Reference

One hundred pennies for your thoughts

I find it difficult to believe that this [Ad-Q] survey was mandated by CMAJ. It has more to do with drug advertising than anything else. Frankly, I find the enclosure of a US$1 bill insulting and not dignified.

Constant Nucci
Obstetrician–Gynecologist
Montreal, Que.

Can you please explain the enclosure of an American dollar bill for the completion of a survey issued by CMAJ?

Darlene Hammell
Physician
Victoria, BC

[The Editor of CMAJ responds:]

The costs associated with producing CMAJ (and most other general medical journals) are largely offset by advertising by pharmaceutical firms. Occasionally readers complain about the number of ads in CMAJ, and some suggest that we cut advertising completely. But this is not a reasonable option for an association journal that is received as a benefit of membership by more than 50 000 CMA physicians and wants to remain affordable to subscribers such as libraries, researchers and physicians in other countries.

Without advertising the only alternative would be to increase CMA membership dues and journal subscription prices.

Information on the types and numbers of physicians who see their advertisements in various journals helps companies to decide how to spend their advertising dollars. CMAJ participates in 2 surveys a year to get feedback from readers on both advertising and editorial content. The latter gives us some information on the types of articles that CMAJ readers like and dislike. We value this feedback, and thank those of you who have participated for your comments (positive or otherwise).

The surveys are conducted by Harvey Research of Fairport, NY; no Canadian company offers a comparable program. The firm’s decision to offer CMAJ readers a US$1 bill as a token of thanks for participating in the survey is unfortunate. Thank you for bringing this to our attention. We thought of asking the firm to use a Canadian loonie, but this would be clunky. (Or we could suggest a Canadian $5 bill, which might shortly be equivalent to a US$1 bill ... but I digress.) We’ve forwarded your comments to Harvey Research.

You’ve each returned to us the US dollar you received. We’ve included them in our contribution to a local charity.

Pity the NHS

In his review of the report of the commission on the British National Health Service (NHS),1 Terrence Sullivan says that the United Kingdom spends a third less on health care than Canada but provides broader coverage. The coverage may indeed be broader, but it is spread a great deal thinner.

The NHS has been starved of money almost from its inception, and I am sure that Canadians would not accept the strictures imposed by spending a third less on their own health care system. Somehow, health care policy planners in Canada have felt that savings of this magnitude have been achieved in Britain by the panacea of capitation and salary as the payment options for physicians. This is not the case.

First, these savings have been achieved by avoiding necessary hospital upgrades. For example, until the early 1990s, the main referral hospital for the county of Somerset was still using Quonset huts for its wards. They were erected by the Americans in 1944, prior to the D-Day invasion.

Second, staff salaries were saved by employing foreign graduates, which robbed developing countries of the physicians and nurses they had used so much of their limited resources to train.

The third saving in the NHS involves rationing by death. By keeping elderly patients waiting many years for their operations, the NHS avoids a large percentage of hip replacements and other operations.

The commission that Sullivan reviewed sounds like the changing of the officers on the bridge after the Titanic has hit the iceberg. The NHS has tried everything from fund-holding practices to a Charter of Rights for patients, but it will remain a second-class service for most users unless it receives dramatically more funding. Unfortunately, this is unlikely to happen in an elitist society where efficient, fee-for-service private care is always available for the affluent.

Paul Cary
Physician
Cambridge, Ont.

Reference

[The author responds:]

Paul Cary makes several important and worthwhile points. However, in discussing why the British spend one-third less on health care than Canadians, he suggests that ‘health care policy planners in Canada have felt that savings of this magnitude have